Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.
Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications.
Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
December 2017—Abacus Diagnostica received the CE mark for the GenomEra Norovirus, a molecular in vitro diagnostic test for the detection and differentiation of norovirus genogroups I and II. The test runs on the GenomEra CDX platform.
December 2017—LabCorp and Cancer Genetics have signed agreements with Thermo Fisher Scientific to join the Next-Generation Sequencing Companion Dx Center of Excellence Program. Each laboratory will participate in oncology-focused clinical trials in collaboration with pharmaceutical companies and Thermo Fisher.
December 2017—ArcherDx has earned ISO 13485:2003 and EN ISO 13485:2012 certification from the British Standards Institution. This ISO certification indicates that the company’s quality management system maintains standards specific to medical devices, including in vitro diagnostic assays.
December 2017—Quidel received 510(k) clearance from the FDA to market its Sofia Lyme FIA for the rapid differential detection of human IgM and IgG antibodies to Borrelia burgdorferi from serum and plasma specimens from patients suspected of B. burgdorferi infection. The test is intended for use with the Sofia analyzer to aid in the diagnosis of Lyme disease.
December 2017—Hologic has received FDA 510(k) clearance for its Panther Fusion Paraflu assay, a multiplexed assay that runs on the Panther Fusion system.
December 2017—Natera announced a second research collaboration with Denmark’s Aarhus University utilizing the company’s research use only technology to evaluate ctDNA as a useful biomarker for detecting minimal residual disease, treatment response, and disease recurrence in colorectal cancer patients. (The university will also use the Signatera technology in a bladder cancer study.)
December 2017—Olympus released its IXplore SpinSR10 imaging system, which aims to balance speed, resolution, and efficiency in a single, flexible platform. A high frame rate and 120 nm XY resolution enable researchers to observe the fine details and workings of internal cellular structures while offering the ability to switch between super-resolution, confocal, and wide-field imaging modes.
November 2017—Beckman Coulter Diagnostics received CE mark clearance for a high-sensitivity troponin assay that aids in diagnosing myocardial infarction for patients presenting with chest pain or other ischemic symptoms.
November 2017—DiaSorin Molecular announced the U.S. introduction of the Simplexa C. difficile Direct Assay upon receiving clearance from the Food and Drug Administration.
November 2017—Natera announced that its Panorama noninvasive prenatal test is validated to screen twin pregnancies for zygosity and chromosomal abnormalities. Panorama can tell the difference between the mother’s and the baby’s DNA, enabling it to distinguish between each twin’s DNA.
